Leah J Ricketson1, Otto G Vanderkooi2, Melissa L Wood1, Jenine Leal1, James D Kellner3. 1. Department of Pediatrics, University of Calgary, and Alberta Health Services - Calgary Zone, University of Calgary, Calgary, Alberta. 2. Department of Pediatrics, University of Calgary, and Alberta Health Services - Calgary Zone, University of Calgary, Calgary, Alberta ; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta ; Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta ; Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Alberta. 3. Department of Pediatrics, University of Calgary, and Alberta Health Services - Calgary Zone, University of Calgary, Calgary, Alberta ; Alberta Children's Hospital Research Institute, University of Calgary, Calgary, Alberta.
Abstract
UNLABELLED: The recent introduction of the seven-valent pneumococcal conjugate vaccine has led to changes in the proportion of disease caused by different serotypes. The serotypes targeted by the vaccine have been reduced, and Streptococcus pneumonia serotype 19A is now the most commonly isolated serotype causing invasive pneumococcal disease. This serotype has been associated with antibiotic resistance. The authors of this article conducted a review of cases of invasive pneumococcal disease diagnosed between 2000 and 2010 in Calgary, Alberta, to examine the disease course of serotype 19A invasive pneumococcal disease compared with other serotypes. BACKGROUND: Streptoccocus pneumoniae serotype 19A (ST19A) became an important cause of invasive pneumococcal disease (IPD) after the introduction of the conjugate vaccine. OBJECTIVE: To examine the severity and outcome of ST19A IPD compared with non-ST19A IPD. METHODS: The Calgary Area Streptococcus pneumoniae Epidemiology Research (CASPER) study collects clinical and laboratory data on all IPD cases in Calgary, Alberta. Analysis was performed on data from 2000 to 2010 comparing ST19A and non-ST19A IPD cases. Adjusted linear and logistic regression models were used to examine outcomes of duration of appropriate intravenous antibiotic therapy and intensive care unit admission, respectively. RESULTS: ST19A tended to cause disease in younger patients. ST19A isolates were more often multidrug resistant (19% versus 0.3%; P<0.001). Adjusted logistic regression showed no difference in intensive care unit admission between ST19A and non-ST19A IPD cases (OR 1.4 [95% CI 0.8 to 2.7]). An adjusted linear regression model showed patients <18 years of age with a diagnosis of bacteremia and no risk factors infected with ST19A were, on average, treated with antibiotics 1.4 times (95% CI 1.1 to 1.9) as long as patients with non-19A IPD and the same baseline characteristics. DISCUSSION: ST19A IPD was associated with an increase in average time on antibiotics. Although many of the infecting strains of ST19A were within the threshold for susceptibility, they may be sufficiently resilient to require a longer duration of antibiotic therapy or higher dose to clear the infection. CONCLUSIONS: ST19A is more common in younger individuals, is more antibiotic resistant and may require longer average treatment duration.
UNLABELLED: The recent introduction of the seven-valent pneumococcal conjugate vaccine has led to changes in the proportion of disease caused by different serotypes. The serotypes targeted by the vaccine have been reduced, and Streptococcus pneumonia serotype 19A is now the most commonly isolated serotype causing invasive pneumococcal disease. This serotype has been associated with antibiotic resistance. The authors of this article conducted a review of cases of invasive pneumococcal disease diagnosed between 2000 and 2010 in Calgary, Alberta, to examine the disease course of serotype 19Ainvasive pneumococcal disease compared with other serotypes. BACKGROUND: Streptoccocus pneumoniae serotype 19A (ST19A) became an important cause of invasive pneumococcal disease (IPD) after the introduction of the conjugate vaccine. OBJECTIVE: To examine the severity and outcome of ST19A IPD compared with non-ST19A IPD. METHODS: The Calgary Area Streptococcus pneumoniae Epidemiology Research (CASPER) study collects clinical and laboratory data on all IPD cases in Calgary, Alberta. Analysis was performed on data from 2000 to 2010 comparing ST19A and non-ST19A IPD cases. Adjusted linear and logistic regression models were used to examine outcomes of duration of appropriate intravenous antibiotic therapy and intensive care unit admission, respectively. RESULTS: ST19A tended to cause disease in younger patients. ST19A isolates were more often multidrug resistant (19% versus 0.3%; P<0.001). Adjusted logistic regression showed no difference in intensive care unit admission between ST19A and non-ST19A IPD cases (OR 1.4 [95% CI 0.8 to 2.7]). An adjusted linear regression model showed patients <18 years of age with a diagnosis of bacteremia and no risk factors infected with ST19A were, on average, treated with antibiotics 1.4 times (95% CI 1.1 to 1.9) as long as patients with non-19A IPD and the same baseline characteristics. DISCUSSION: ST19A IPD was associated with an increase in average time on antibiotics. Although many of the infecting strains of ST19A were within the threshold for susceptibility, they may be sufficiently resilient to require a longer duration of antibiotic therapy or higher dose to clear the infection. CONCLUSIONS: ST19A is more common in younger individuals, is more antibiotic resistant and may require longer average treatment duration.
Authors: K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney Journal: JAMA Date: 2001-04-04 Impact factor: 56.272
Authors: William P Hanage; Tarja H Kaijalainen; Ritva K Syrjänen; Kari Auranen; Maija Leinonen; P Helena Mäkelä; Brian G Spratt Journal: Infect Immun Date: 2005-01 Impact factor: 3.441
Authors: Walter H B Demczuk; Irene Martin; Averil Griffith; Brigitte Lefebvre; Allison McGeer; Amanda Shane; George G Zhanel; Gregory J Tyrrell; Matthew W Gilmour Journal: Can J Microbiol Date: 2012-07-24 Impact factor: 2.419
Authors: James D Kellner; Otto G Vanderkooi; Judy MacDonald; Deirdre L Church; Gregory J Tyrrell; David W Scheifele Journal: Clin Infect Dis Date: 2009-07-15 Impact factor: 9.079
Authors: Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage Journal: Pediatr Infect Dis J Date: 2007-06 Impact factor: 2.129
Authors: Eun Hwa Choi; So Hee Kim; Byung Wook Eun; Sun Jung Kim; Nam Hee Kim; Jina Lee; Hoan Jong Lee Journal: Emerg Infect Dis Date: 2008-02 Impact factor: 6.883